Jeremy Faust saves lives in the ER and breaks stories with his Inside Medicine newsletter. He’s also testing the bounds of ...
Damian covers the global drug industry and contributes to STAT’s industry-leading events. You can reach Damian on Signal at damiangarde.67. Good morning, everyone. Damian Garde here, filling in for Ed ...
An outbreak of diarrhea-causing parasite has grown to more than 1,000 cases, making it one of the nation’s largest such ...
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive ...
An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs ...
Today, in STAT’s Brooklyn outpost we’re drinking — yes, heresies of heresies — plain old water. Sometimes you have to give ...
Longevity entrepreneur Bryan Johnson shared some bad news on social media recently. “I have an autoimmune disease. My stomach ...
Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
We’re here in STAT’s Brooklyn outpost today, where everyone’s gazing across the East River to see whether Pfizer’s former ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
For the second year in a row, many Affordable Care Act insurers are proposing double-digit premium increases, driven by ...
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene ...
It’s time to bring production of essential medications back to the U.S. — or at least closer to home. The meeting, described ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results